A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients (DOM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by University of Turku.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
University of Turku
ClinicalTrials.gov Identifier:
NCT00733083
First received: August 8, 2008
Last updated: NA
Last verified: August 2008
History: No changes posted

August 8, 2008
August 8, 2008
September 2008
December 2009   (final data collection date for primary outcome measure)
The difference of needed rescue pain medication post operatively [ Time Frame: predetermined intervals being 15 min during the first postoperative hour, followed by interval of 30 min for 4 first postop hours. At home pain and adverse effects are registered by parent at 24 hours and 48 hours. ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
differences in adverse effects [ Time Frame: In hospital 4 hours with first hour in 15 min intervals, then 30 min. At home 24+48h ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
A Comparative Study With Pre-Emptive Parenteral Oxycodone, Morphine and Dexamethasone in the Treatment of Postoperative Pain in Paediatric Patients 4 to 12 Years of Age

The aim of this randomized, double-blind study is to compare parenteral pre-emptive oxycodone, morphine and dexamethasone with placebo in the treatment of postoperative pain in paediatric patients 4 to 12 years of age. The investigators hope to find out whether there are any differences in postoperative pain and/or adverse effects among these groups.

After the induction of anaesthesia and before intubation the child receives one of the research drugs in a double-blind fashion: 0.1 mg/kg of oxycodone , 0.1 mg/kg of morphine, 0.5 mg/kg dexamethasone (max 24 mg), or placebo. All the research drugs are diluted into a dose of 10 ml with NaCl 0.9%, the placebo being solely the dilute.

The patients are followed minimum 4h postoperatively: first in the recovery room, and after the patient is stable enough the study is continued in the day-patient unit. Level of pain and adverse effects are registered all on same predetermined intervals being 15 min during the first postoperative hour, followed by interval of 30 min until the discharge.

The safety measurements noted include pulse, respiratory rate, non-invasive blood pressure and peripheral oxygen saturation are recorded on the same intervals The registering of pain, adverse effects and given medication continues at home for 48 hours post operatively with a questionnaire filled by the parents.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Post Tonsillectomy Pain
  • Drug: 0,1 mg/kg of oxycodone
    solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
    Other Name: Oxynorm
  • Drug: Morphine 0,1 mg/kg
    solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
    Other Name: Morphin
  • Drug: Dexamethasone 0,5 mg/kg
    solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
    Other Name: Oradexon
  • Drug: NaCl 0,9%
    solution for injection one injection in the beginning of anesthesia
    Other Name: NaCl 0,9% Braun
  • Active Comparator: 1
    0,1 mg/kg of oxycodone
    Intervention: Drug: 0,1 mg/kg of oxycodone
  • Active Comparator: 2
    0,1 mg/kg of morphine
    Intervention: Drug: Morphine 0,1 mg/kg
  • Active Comparator: 3
    0,5 mg/kg dexamethasone (max 24 mg
    Intervention: Drug: Dexamethasone 0,5 mg/kg
  • Placebo Comparator: 4
    NaCl 0,9%
    Intervention: Drug: NaCl 0,9%
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
December 2010
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 4 to 12 years of age
  • Scheduled to tonsillectomy
  • ASA class I or II
  • Written informed consent is obtained from the parents and the child (when appropriate).

Exclusion Criteria:

  • Allergy to morphine, oxycodone or dexamethasone
Both
4 Years to 12 Years
No
Contact: Mari S Aallos-Ravenna, MD +35823130655 mari.aallos-ravenna@tyks.fi
Contact: Tuula Manner, MD +35823130962 tuula.manner@tyks.fi
Finland
 
NCT00733083
DOM
No
MD, PhD Tuula Manner, Turku university hospital, Finland
University of Turku
Not Provided
Principal Investigator: Tuula Manner, MD, PhD Turku University Hospital
University of Turku
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP